Evidence map›Paper›PMID 27531241›Full record

ArticleHepatology (Baltimore, Md.)2016

Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.

Shadi Salloum, Jacinta A Holmes, Rohit Jindal, Shyam S Bale, Cynthia Brisac, Nadia Alatrakchi, Anna Lidofsky, Annie J Kruger, Dahlene N Fusco, Jay Luther and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 43 citations in OpenAlex.

  1. Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. HIV and liver disease: a comprehensive update.Topics in antiviral medicine · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. HIV and the liver.Topics in antiviral medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Shadi SalloumGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Jacinta A HolmesGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Rohit JindalCenter for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Shyam S BaleCenter for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Cynthia BrisacGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Nadia AlatrakchiGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Anna LidofskyGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Annie J KrugerGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Dahlene N FuscoGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Jay LutherGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Esperance A SchaeferGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Wenyu LinGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Martin L YarmushCenter for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Raymond T ChungGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Harvard University · USMassachusetts General Hospital · US

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease ProgressionR01DK098079 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2013 to 2016
$2.7M
HIV-Associated Macrophage Alterations and Progressive Liver DiseaseR01DK108370 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2015 to 2019
$1.6M
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease ProgressionR56DK098079 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2012 to 2012
$506k
NIDDK NIH HHS P30 DK043351NIDDK NIH HHS R01 DK098079NIDDK NIH HHS R01 DK108370NIDDK NIH HHS R56 DK098079
6 · The paper itself

Abstract

Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection accelerates progressive liver fibrosis; however, the mechanisms remain poorly understood. HCV and HIV independently induce profibrogenic markers transforming growth factor beta-1 (TGFβ1) (mediated by reactive oxygen species [ROS]) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) in hepatocytes and hepatic stellate cells in monoculture; however, they do not account for cellular crosstalk that naturally occurs. We created an in vitro coculture model and investigated the contributions of HIV and HCV to hepatic fibrogenesis. Green fluorescent protein reporter cell lines driven by functional ROS (antioxidant response elements), NFκB, and mothers against decapentaplegic homolog 3 (SMAD3) promoters were created in Huh7.5.1 and LX2 cells, using a transwell to generate cocultures. Reporter cell lines were exposed to HIV, HCV, or HIV/HCV. Activation of the 3 pathways was measured and compared according to infection status. Extracellular matrix products (collagen type 1 alpha 1 (CoL1A1) and tissue inhibitor of metalloproteinase 1 (TIMP1)) were also measured. Both HCV and HIV independently activated TGFβ1 signaling through ROS (antioxidant response elements), NFκB, and SMAD3 in both cell lines in coculture. Activation of these profibrotic pathways was additive following HIV/HCV coexposure. This was confirmed when examining CoL1A1 and TIMP1, where messenger RNA and protein levels were significantly higher in LX2 cells in coculture following HIV/HCV coexposure compared with either virus alone. In addition, expression of these profibrotic genes was significantly higher in the coculture model compared to either cell type in monoculture, suggesting an interaction and feedback mechanism between Huh7.5.1 and LX2 cells.

conclusionHIV accentuates an HCV-driven profibrogenic program in hepatocyte and hepatic stellate cell lines through ROS, NFκB, and TGFβ1 up-regulation; coculture of hepatocyte and hepatic stellate cell lines significantly increased expression of CoL1A1 and TIMP1; and our novel coculture reporter cell model represents an efficient and more authentic system for studying transcriptional fibrosis responses and may provide important insights into hepatic fibrosis. (Hepatology 2016;64:1951-1968).

Indexed as

Transcriptional ActivationCell LineCoculture TechniquesHepacivirusHepatic Stellate CellsHepatocytesHIVHumansLiver CirrhosisNF-kappa BNF-kappa B

Identifiers

PMID27531241
PMCPMC5116014
OpenAlexW2510120867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.